Open label, single arm safety prospective cohort study of dabigatran etexilate for secondary prevention of venous thromboembolism in children from 0 to less than 18 years
Phase of Trial: Phase III
Latest Information Update: 06 Apr 2018
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 27 Mar 2018 This trial has been suspended in Spain.
- 02 Mar 2018 This trial has been suspended in Finland.
- 22 Feb 2018 This trial has been suspended in Denmark.